Molecular Oncology
Volume 1, Issue 4 , Pages 384-394 , April 2008

High throughput molecular diagnostics in bladder cancer – on the brink of clinical utility

Received 5 November 2007 ,Accepted 30 November 2007.

References 

  1. Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 2007 Aug 1;13(15 Pt 1):4407–4414
  2. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 2004 Jun 15;22(12):2284–2293
  3. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005 Apr 14;434(7035):864–870
  4. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer. 2006 Feb;6(2):107–116
  5. Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, ez de Medina SG, Cappellen D, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006 Apr;27(4):740–747
  6. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006 Jan 19;439(7074):353–357
  7. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de MS, Van RB, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 2001 Jun;158(6):1955–1959
  8. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012–7022
  9. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 2005 Jun 1;11(11):4044–4055
  10. Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer. 2004 Dec 1;101(11):2540–2548
  11. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer. 2007 May;56(2):175–184
  12. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 2007 Feb 10;25(5):517–525
  13. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl. Cancer Inst. 2007 Jan 17;99(2):147–157
  14. Dyrskjøt L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 2003 Jan;33(1):90–96
  15. Dyrskjøt L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004 Jun 1;64(11):4040–4048
  16. Dyrskjøt L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res. 2005 Jun 1;11(11):4029–4036
  17. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res. 2007 Jun 15;13(12):3545–3551
  18. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 2006 Aug 10;355(6):560–569
  19. Fox EJ, Leahy DT, Geraghty R, Mulcahy HE, Fennelly D, Hyland JM, et al. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J. Mol. Diagn. 2006 Feb;8(1):68–75
  20. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002 Nov 15;62(22):6418–6423
  21. Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA. Microarrays in breast cancer research and clinical practice—the future lies ahead. Endocr. Relat. Cancer. 2006 Dec;13(4):1017–1031
  22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70
  23. Hoque MO, Lee J, Begum S, Yamashita K, Engles JM, Schoenberg M, et al. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res. 2003 Sep 15;63(18):5723–5726
  24. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 2003 May 1;63(9):2216–2222
  25. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96
  26. Hughes SJ, Xi L, Raja S, Gooding W, Cole DJ, Gillanders WE, et al. A rapid, fully automated, molecular-based assay accurately analyzes sentinel lymph nodes for the presence of metastatic breast cancer. Ann. Surg. 2006 Mar;243(3):389–398
  27. Jensen EH, McLoughlin JM, Yeatman TJ. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand?. Curr. Opin. Oncol. 2006 Jul;18(4):374–380
  28. Kemming D, Vogt U, Tidow N, Schlotter CM, Burger H, Helms MW, et al. Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction. Mol. Diagn. Ther. 2006;10(5):271–280
  29. Killian A, Di FF, Le PF, Blanchard F, Lamy A, Raux G, et al. A simple method for the routine detection of somatic quantitative genetic alterations in colorectal cancer. Gastroenterology. 2007 Feb;132(2):645–653
  30. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and non-papillary pathways. Lab. Invest. 2005 Apr;85(4):532–549
  31. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis. 2006 Mar;27(3):361–373
  32. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res. 2005 Jan 1;65(1):34–45
  33. Korn R, Rohrig S, Schulze-Kremer S, Brinkmann U. Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes. Bioinformatics. 2005 Jun 1;21(11):2766–2772
  34. Lai LA, Paulson TG, Li X, Sanchez CA, Maley C, Odze RD, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer. 2007 Jun;46(6):532–542
  35. Lebret T, Watson RW, Molinie V, Poulain JE, O'Neill A, Fitzpatrick JM, et al. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur. Urol. 2007 Jan;51(1):161–166
  36. Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin. Cancer Res. 2007 Jan 15;13(2 Pt 1):498–507
  37. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006 Apr 27;25(18):2685–2696
  38. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from non-cancer patients. Eur. Urol. 2005 Apr;47(4):456–462
  39. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005 Feb 5;365(9458):488–492
  40. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 2006 Dec 10;24(35):5552–5564
  41. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res. 2004 May 15;10(10):3410–3421
  42. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, et al. Urinary biomarker profiling in transitional cell carcinoma. Int. J. Cancer. 2006 Dec 1;119(11):2642–2650
  43. Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000 Aug 1;60(15):4021–4025
  44. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2007 Mar 1;26(10):1507–1516
  45. Nakao K, Mehta KR, Fridlyand J, Moore DH, Jain AN, Lafuente A, et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis. 2004 Aug;25(8):1345–1357
  46. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet. 2003 Oct 15;12 Spec;No 2:R153–R157
  47. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004 Aug 15;10(16):5367–5374
  48. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003 Nov 1;362(9394):1439–1444
  49. Patard JJ, Rodriguez A, Lobel B. The current status of intravesical therapy for superficial bladder cancer. Curr. Opin. Urol. 2003 Sep;13(5):357–362
  50. Paterson AL, Pole JC, Blood KA, Garcia MJ, Cooke SL, Teschendorff AE, et al. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer. 2007 May;46(5):427–439
  51. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006;8(2):R23
  52. Pospisil P, Iyer LK, Adelstein SJ, Kassis AI. A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics. 2006;7:354
  53. Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, et al. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer. 2007 Jul;46(7):661–669
  54. Reddy GK, Balk SP. Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer. Clin. Genitourin Cancer. 2006 Dec;5(3):187–189
  55. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res. 2003 Dec 15;63(24):8861–8868
  56. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol. 2003 Aug;163(2):505–516
  57. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 2006 Feb 10;24(5):778–789
  58. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur. Urol. 2004 Mar;45(3):292–296
  59. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, et al. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int. J. Cancer. 2006 Oct 15;119(8):1915–1919
  60. Sorensen FJ, Andersen CL, Wiuf C. SNPTools: a software tool for visualization and analysis of microarray data. Bioinformatics. 2007 Mar 28;
  61. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127
  62. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat. Rev. Cancer. 2007 Jul;7(7):545–553
  63. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006 Feb 15;98(4):262–272
  64. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005 Oct 25;102(43):15545–15550
  65. Sun Z, Yang P. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol. Biomarkers Prev. 2006 Nov;15(11):2063–2068
  66. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 2005 Apr 1;11(7):2625–2636
  67. Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2007 Jan;98(1):113–117
  68. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin. Cancer Res. 2004 Jun 1;10(11):3800–3806
  69. Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, Kakar S, et al. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin. Cancer Res. 2006 Nov 1;12(21):6379–6385
  70. Vauhkonen H, Vauhkonen M, Sajantila A, Sipponen P, Knuutila S. Characterizing genetically stable and unstable gastric cancers by microsatellites and array comparative genomic hybridization. Cancer Genet. Cytogenet. 2006 Oct 15;170(2):133–139
  71. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001 Apr;158(4):1491–1502
  72. Warnat P, Eils R, Brors B. Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics. 2005;6:265
  73. Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, et al. Gene expression profiling of progressive papillary non-invasive carcinomas of the urinary bladder. Clin. Cancer Res. 2005 Jun 15;11(12):4415–4429
  74. Wolf H, Iversen HG, Rosenkilde P, Schroder T. Transurethral surgery in the treatment of invasive bladder cancer (T1 and T2). Scand. J. Urol. Nephrol. Suppl. 1987;104:127–132
  75. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006 Jan;3(1):e13
  76. Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin. Cancer Res. 2005 Nov 1;11(21):7709–7719

PII: S1574-7891(07)00101-9

doi: 10.1016/j.molonc.2007.11.002

Molecular Oncology
Volume 1, Issue 4 , Pages 384-394 , April 2008

Article Tools

* Image Usage & Resolution